Guidelines Overview: Augmentation Therapies in Major Depressive Disorder
  • CME

This concise CME-certified activity provides insights from an expert on how to implement guideline-based care for your patients with MDD who require treatment augmentation.
Roger McIntyre, MD, FRCPC
Physicians: maximum of 1.0 AMA PRA Category 1 Credit
Released: February 26, 2020 Expiration: February 25, 2021

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Develop patient-tailored treatment plans that include guideline-directed augmentation strategies to manage residual MDD symptoms
  • Incorporate recommended assessment tools in the evaluation of the patient response to antidepressant therapy to guide treatment modification in MDD

Acknowledgements

Provided by Clinical Care Options, LLC

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA

Sophia Kelley
(203)-316-2125
skelley@clinicaloptions.com
www.clinicaloptions.com

Supported by an educational grant from
Otsuka and Lundbeck Alliance

Information on this Educational Activity

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty

Roger McIntyre, MD, FRCPC

Professor of Psychiatry and Pharmacology
Department of Psychiatry/Pharmacology
University of Toronto
Head, Mood Disorders Psychopharmacology Unit
Department of Psychiatry
Toronto, Canada

Roger S. McIntyre, MD, FRCPC, has disclosed that he has received consulting fees from Allergan, Janssen, Lundbeck, Minerva, Neurocrine, Otsuka, Pfizer, Purdue, Shire, Sunovion, and Takeda and funds for research support from Stanley Medical Research Institute.

Staff

Zachary Schwartz, MSc

Scientific Director

Zachary Schwartz, MSc, ELS, has no relevant conflicts of interest to report.
Kiran D. Mir-Hudgeons, PhD

Manager, Editorial Operations

Kiran Mir-Hudgeons, PhD, has no relevant conflicts of interest to report.
Carolyn Skowronski, PharmD

Associate Director, Scientific Services

Carolyn Skowronski, PharmD, has no relevant conflicts of interest to report.
Katherine Kahn
Katherine Kahn has no relevant conflicts of interest to report.
Anne Roc, PhD
Director, Scientific Services
Anne Roc, PhD, has no relevant conflicts of interest to report.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Target Audience

This activity is intended primarily for psychiatrists and primary care physicians who care for patients with MDD.

Goal

The goal of this activity is to improve the learner’s competence in selecting treatment augmentation modalities (eg, dosage changes, antidepressant switching, adding atypical antipsychotic) for patients with MDD who respond suboptimally to antidepressant therapy.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Program Medium

This program has been made available online.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from February 26, 2020, through February 25, 2021:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Related Content

From CCO: Companion Migraine Comorbidities slideset with highlights from Do-It-Better RealCME on Improving Migraine Treatment, and Prevention.

Jessica Ailani, MD Released: June 25, 2020

Patient cases on comorbidities in migraine, including sleep disorders, depression, and more

Jessica Ailani, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Released: May 28, 2020 Expired: May 28, 2021

Enter MDD patient characteristics in this online CCO tool and compare your treatment plan with those of 5 experts

Leslie Citrome, MD, MPH Christoph U. Correll, MD Rakesh Jain, MD, MPH Roger McIntyre, MD, FRCPC Michael E. Thase, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Released: April 17, 2020 Expired: April 16, 2021

Concise CME on managing common comorbidities in patients with MDD, including obesity, cardiovascular disease, and substance use disorder

Christoph U. Correll, MD Physicians: maximum of 1.0 AMA PRA Category 1 Credit Released: April 13, 2020 Expired: April 12, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.

Continue

More info

CCO’s educational programs are available completely free of charge on the ClinicalOptions.com, inPractice.com, and inPracticeAfrica.com Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?